Clinical data shows the combination produces significantly greater weight loss than either agent alone
Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH
Cagrilintide has emerged as one of the most scientifically significant metabolic research compounds of the current era, primarily through its complementary mechanism to GLP-1 receptor agonists like Semaglutide and dual agonists like Tirzepatide
Injectable use typically produces only mild injection-site reactions
Certain groups should exercise particular caution or avoid BPC-157 entirely: individuals with active cancer or significant cancer history, pregnant or breastfeeding women (no safety data exists), those taking blood thinners (potential interaction effects), and anyone with autoimmune conditions affecting connective tissue